KKR, EQT Reportedly Eyeing $1.3B PolyPeptide Takeover
Summary
KKR & Co. is reportedly among private equity firms, including EQT, expressing interest in a potential takeover of Swiss contract drugmaker PolyPeptide Group AG, which has a market value of approximately $1.3 billion. This potential M&A activity aligns with KKR's recent aggressive capital deployment, coming shortly after the firm secured $23 billion for its latest Americas private equity fund and launched a $3.48 billion tender offer to privatize Taiyo Holdings. While the report notes that deliberations are ongoing and a transaction is not certain, this news signals KKR's continued appetite for significant acquisitions. Traders should monitor for any official announcements or further details regarding a potential bid for PolyPeptide.
At the time of this announcement, KKR was trading at $90.57 on NYSE in the Finance sector, with a market capitalization of approximately $80.7B. The 52-week trading range was $82.67 to $153.87. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.